💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Allopurinol Sodium

CHEMBL1200477 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
158.1 g/mol
LogP
—
Phase
4

The sodium salt form of allopurinol used as an intravenous preparation for patients who cannot take oral medication, providing the same xanthine oxidase inhibition to reduce uric acid production and prevent crystal deposition in joints, kidneys, and other tissues.

Molekularmasse

158,0900 g/mol

TPSA

77,50 Ų

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Schizophrenia Bipolar Disorder Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Gout Tuberculosis Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Wirkmechanismus

Xanthine oxidase inhibitor reducing uric acid production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Xanthine oxidase inhibitor reducing uric acid production.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=c1[n-]cnc2[nH]ncc12.[Na+]

                

                

                
                

                    
InChI

                    
InChI=1S/C5H4N4O.Na/c10-5-3-1-8-9-4(3)6-2-7-5;/h1-2H,(H2,6,7,8,9,10);/q;+1/p-1

                

                

                

                    
                    

                        
Molecular Formula

                        
C5H3N4NaO

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
Rotierbare Bindungen

                        
0

                    

                    
                    
                    

                        
Schwere Atome

                        
11

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
The sodium salt form of allopurinol used as an intravenous preparation for patients who cannot take oral medication, providing the same xanthine oxidase inhibition to reduce uric acid production and prevent crystal deposition in joints, kidneys, and other tissues.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Xanthine oxidase inhibitor reducing uric acid production.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Allopurinol Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200477.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 23662349.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.